peoplePerson
Charles D. Blanke
Charles Blanke is a GI oncologist who chaired SWOG for a decade and led early imatinib trials in GIST.
Medical oncologist who was SWOG group chair from 2013 to 2025 and now serves as chief medical officer. Led pivotal imatinib dose trials in gastrointestinal stromal tumour.
Role
Chief Medical Officer, SWOG Cancer Research Network; Professor, Oregon Health & Science University
Institution
Specialisms
Gastrointestinal oncologyGISTClinical trial leadership
Pages like this
not linked directly; found by shared links- TrialSSGXVIII/AIO (adjuvant imatinib in GIST)
Shares KIT, Imatinib, Sarcomas (soft tissue, bone, GIST).
- PersonHagen F. Kennecke
- TermSarcoma (tissue type)
Shares KIT, Imatinib, Sarcomas (soft tissue, bone, GIST).
- TrialINVICTUS
Shares KIT, Sarcomas (soft tissue, bone, GIST).
- PersonJean-Yves Blay
Shares KIT, Imatinib, Sarcomas (soft tissue, bone, GIST).
- PersonYoon-Koo Kang
Shares KIT, Imatinib, Sarcomas (soft tissue, bone, GIST).
- PairingctDNA KIT genotyping → TKI selection in GIST
Shares KIT, Sarcomas (soft tissue, bone, GIST).
- TrialINSIGHT
Shares KIT, Sarcomas (soft tissue, bone, GIST).